FibroGen (FGEN)

• Market cap: $30.9M
• 1 day: 2.03%
• 5 days: -9.09%
• 1 month: -19.57%
• 3 months: -42.15%
• 6 months: -23.43%
• Year to date: -42.15%
• 1 year: -85.82%
• 5 years: -99.10%
• 10 years: -99.01%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.

Employees: 225

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

300% more call options, than puts

Call options by funds: $336K | Put options by funds: $84K

0% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]

0% less capital invested

Capital invested by funds: $19.5M [Q3] → $19.5M (-$54.4K) [Q4]

4% less funds holding

Funds holding: 72 [Q3] → 69 (-3) [Q4]

10.9% less ownership

Funds ownership: 47.42% [Q3] → 36.51% (-10.9%) [Q4]

21% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 14

36% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 22

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $10 3,166% upside
• Avg. target: $10 3,166% upside
• High target: $10 3,166% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Joseph Pantginis 19% 1-year accuracy 78 / 419 met price target

3,166% upside $10

Buy Reiterated

18 Mar 2025